probucol has been researched along with Bright Disease in 4 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogawa, M | 1 |
| Ueda, S | 1 |
| Anzai, N | 1 |
| Ito, K | 1 |
| Ohto, M | 1 |
| Akikusa, B | 1 |
| Neale, TJ | 2 |
| Ojha, PP | 1 |
| Exner, M | 1 |
| Poczewski, H | 1 |
| Rüger, B | 1 |
| Witztum, JL | 1 |
| Davis, P | 1 |
| Kerjaschki, D | 2 |
| Mimura, K | 1 |
| Yukawa, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy[NCT00050713] | Phase 2 | 12 participants (Actual) | Interventional | 2002-12-17 | Completed | ||
| Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy[NCT00977977] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for probucol and Bright Disease
| Article | Year |
|---|---|
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
1 trial available for probucol and Bright Disease
| Article | Year |
|---|---|
Decrease of urine protein after treatment with probucol in patients with mild glomerulonephritis and arteriolosclerosis.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Female; Glomerulonephritis; Humans; Male; M | 1995 |
2 other studies available for probucol and Bright Disease
| Article | Year |
|---|---|
Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.
Topics: Aldehydes; Animals; Anticholesteremic Agents; Antigen-Antibody Complex; Basement Membrane; Cholester | 1994 |
[Hyperlipidemia and drug treatment].
Topics: Arteriosclerosis; Carnitine; Cholestyramine Resin; Glomerulonephritis; Humans; Hyperlipidemias; Kidn | 1991 |